Document is current
Any future updates will be listed below
-
Authors
Chen, Shu https://orcid.org/0009-0000-0112-7503
Zhang, Xi
Basappa, Basappa https://orcid.org/0000-0002-8844-468X
Zhu, Tao https://orcid.org/0000-0003-4130-1144
Pandey, Vijay https://orcid.org/0000-0001-8704-0694
Lobie, Peter E. https://orcid.org/0000-0002-8445-184X
- License Information
-
More Information
Article History
Received: 17 July 2024
Accepted: 13 December 2024
First Online: 21 February 2025
Competing interests
: The authors declare the following competing interests43: P.E.L. and T.Z. have previously consulted for Perseis Therapeutics Ltd. P.E.L. is named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. V.K.P., B.B., K.S.R., and P.E.L. are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof). P.E.L. is an equity holder in Sinotar Pharmaceuticals Ltd which currently holds the license for this patent.
